Abstract YO30
Case summary
BACKGROUND
Patients with cancer are at a higher risk for COVID-19 infection with consequently worse outcomes. This case series aim is to understand the demographic, clinical profile and outcomes of cancer patients with COVID-19 in a tertiary hospital in Davao City to provide for better quality of care for this subset of patients.
METHODS
Cancer patients with COVID-19 infection admitted at a tertiary hospital in Davao City were identified. Data were obtained through chart review. Information included were from patients diagnosed from March 2020 to September 22, 2020.
RESULTS
Fourteen cancer patients were diagnosed with COVID-19, with a median age of 45 years (range 19-61 years), and 10 (71%) are females. Three (21%) patients have hypertension and diabetes. Tumors mostly were from the CNS (21%) while breast, GUT, head and neck, lymphoma each represent 14% of the total cases. 64% of patients have stage 4 disease, 3(21%) patients had stage 3. Four (29%) patients had chemotherapy within the last 3 months of admission. Dyspnea (36%), cough (29%) and fatigue (21%) are the most common symptoms. Chest radiograph finding of bilateral infiltrates was seen in 7 (50%) patients. CRP and serum ferritin were the most common laboratory abnormalities seen in 11 (79%) patients. Nine (64%) patients received supplemental oxygen and 4 (29%) needed ventilator assistance. Steroids was given in 3 (21%) patients and 11(79%) received antibiotics. Complications of acute respiratory failure was seen in 5(36%) patients and 2 (14%) had septic shock. There were 6 (43%) COVID-19 related deaths and 7 (50%) patients were discharged. The median length of hospital stay is at 13 days.
CONCLUSIONS
Cancer patients have increased risk of contracting COVID-19 infection and are more likely to have worse COVID-19 disease and outcomes.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06